Apimeds Pharmaceuticals US, Inc. (APUS) — Net Asset Quality Index
Apimeds Pharmaceuticals US, Inc. (APUS) has a Net Asset Quality Index of 88.2% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $9.25 Million minus total liabilities of $1.09 Million yields net assets of $8.16 Million. A higher index indicates a stronger, lower-leverage balance sheet. Also explore how large is Apimeds Pharmaceuticals US, Inc.'s balance sheet for the complete picture of this company's asset base.
Quality Index
Net Assets
Total Assets
Total Liabilities
Apimeds Pharmaceuticals US, Inc. Net Asset Quality Index Over Time (2021–2024)
This chart shows how Apimeds Pharmaceuticals US, Inc.'s Net Asset Quality Index has evolved across 4 annual periods from 2021 to 2024. As of September 2025, the index stands at 88.2%, representing net assets of $8.16 Million against total assets of $9.25 Million USD. See APUS working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Apimeds Pharmaceuticals US, Inc. (2021–2024)
The table below presents the year-by-year Net Asset Quality Index for Apimeds Pharmaceuticals US, Inc. from 2021 to 2024, covering 4 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Apimeds Pharmaceuticals US, Inc. market cap and net worth.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | -10401.5% | $-1.36 Million | $13.06K | $1.37 Million | ▼ -10409.0 pp |
| 2023 | 7.6% | $31.87K | $422.08K | $390.20K | ▲ +11571.4 pp |
| 2022 | -11563.9% | $-713.61K | $6.17K | $719.78K | ▼ -11425.3 pp |
| 2021 | -138.5% | $-238.48K | $172.17K | $410.65K | — |